Welcome to our dedicated page for Rcm Tech SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RCM Technologies, Inc. (RCMT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RCM, a Nevada corporation whose common stock trades on the Nasdaq Capital Market, submits annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy materials such as the definitive proxy statement on Schedule 14A.
In its periodic reports, RCM presents consolidated financial statements and segment information for its Specialty Health Care, Engineering and Life Sciences, Data and Solutions businesses. These filings detail revenue, cost of services, gross profit, operating income, net income, balance sheet data and cash flows, along with discussions of risk factors and management’s analysis of results. The company also discloses its use of non-GAAP measures—Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share—and provides reconciliations to the most directly comparable GAAP figures.
Current reports on Form 8-K for RCM include items such as quarterly earnings press releases furnished under Item 2.02 and changes in the company’s independent registered public accounting firm under Item 4.01. One filing describes the dismissal of WithumSmith+Brown, PC and the engagement of EisnerAmper LLP to audit the company’s financial statements and internal control over financial reporting for a specified fiscal year, as well as the remediation of a previously reported material weakness in certain IT general controls.
The company’s definitive proxy statement (DEF 14A) outlines governance and shareholder matters, including the election of directors, approval of an omnibus equity compensation plan, ratification of the independent accountants, and advisory votes on executive compensation and the frequency of such votes. It also explains voting procedures, record dates, quorum requirements and how stockholders can attend and vote at the virtual annual meeting.
On this page, Stock Titan pairs RCM’s SEC filings with AI-powered summaries to help readers quickly understand the key points in lengthy documents. Filings are updated as they are made available on EDGAR, allowing investors to review RCMT’s financial reporting, auditor changes, executive compensation disclosures and other regulatory information in one place, with plain-language explanations of complex sections.
RCM Technologies, Inc. Chief Financial Officer Kevin D. Miller reported two open-market sales of company common stock under a nondiscretionary Rule 10b5-1 trading plan. He sold 1,483 shares at $32.00 on April 22, 2026 and 2,932 shares at $32.04 on April 24, 2026.
Across both transactions, Miller sold a total of 4,415 shares and continues to hold 443,800 shares of RCM Technologies common stock directly after these sales.
RCM Technologies CFO Kevin D. Miller reported two open-market sales of common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 3,000 shares at $32.00 on April 17, 2026 and 2,385 shares at a weighted-average price of $32.02 on April 20, 2026. After these transactions, he directly holds 448,215 shares of RCM Technologies common stock.
RCMT filed a Form 144 proposing the sale of 75,000 shares of Common Stock. The form lists $2,400,000.00 and a figure of 7,024,377 alongside a date of 04/17/2026 and Baird as broker. Sale methods listed include Open Market, ESPP, Salary Exchange, and RSU Vesting.
RCM Technologies, Inc. Division President, HC Srvs., Michael Saks reported open-market sales of company common stock. He sold a total of 5,000 shares at $30.00 per share in transactions on April 15–16, 2026. Following these sales, he directly owns 104,814 shares of common stock, which include 267 shares purchased through the company’s Employee Stock Purchase Plan. The filing notes that the sales were made under a nondiscretionary Rule 10b5-1 trading plan established on December 6, 2024.
RCM Technologies Executive Chairman & President Bradley Vizi sold 50,000 shares of common stock in open-market transactions at about $30.00 per share. The sales occurred on two dates and were executed under a nondiscretionary plan intended to satisfy Rule 10b5-1.
After these transactions, Vizi directly holds 1,502,477 shares of RCM Technologies common stock, indicating he retains a substantial ownership stake while realizing some liquidity through a pre-established trading plan.
RCMT filing reports an offering and recent Section 144 sale by an employee. The filing lists 4,864 common shares associated with an Employee Stock Purchase Plan and shows 136 shares sold on 04/15/2026 for $4,080.00. The filing was recorded on 04/16/2026.
RCM Technologies Executive Chairman & President Bradley Vizi reported a mix of stock sales and awards in company shares. On April 7–8, he sold 13,666 and 8,237 shares of common stock in open‑market transactions at weighted average prices around $27.55 and $27.52, executed under a nondiscretionary Rule 10b5‑1 trading plan.
He also received 104,266 shares as employment compensation upon vesting of previously granted performance stock units, while 41,029 shares were surrendered to cover related tax obligations through a net share settlement. After these transactions, Vizi directly holds 1,552,477 shares of RCM Technologies common stock, indicating the sales represent a small portion of his overall stake.
RCM Technologies, Inc. submitted a Form 144 notifying proposed sale of Common Stock tied to restricted‑share vesting. The notice lists 96,933 shares dated 01/15/2021, 125,000 shares dated 01/03/2023, and 50,000 shares dated 01/16/2023.
The filing identifies the securities as Common Stock, par value $0.05 and references NASDAQ with a filing date line showing 04/07/2026.
RCM Technologies, Inc. files its annual report, reporting revenue of $319.4 million for the year ended January 3, 2026, up from $278.4 million a year earlier. Specialty Health Care generated 51.4% of revenue, Engineering 37.7%, and Life Sciences, Data and Solutions 10.9%.
The company highlights growing demand tied to telemedicine, behavioral health, cleaner energy infrastructure, and hybrid IT solutions. Two customers accounted for 20.8% and 13.6% of consolidated revenue, and about 9.1% of revenue came from outside the United States.
RCM remained in compliance with its revolving credit covenants, with $24.7 million borrowed and $27.1 million available, and continued a $50 million share repurchase program, buying 114,942 shares in late 2025 at an average price of $19.48.